Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 3/20 | 0.30 |
| ▸ | CA1 | P00915 | 3/20 | 0.30 |
| ▸ | CA2 | P00918 | 3/20 | 0.30 |
| ▸ | CA7 | P43166 | 3/20 | 0.30 |
| ▸ | CA9 | Q16790 | 3/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23884961 | 1.00 | TSHR (0.42) | TSHRHCAR2GAASMN1; SMN2PDCD1 | |
| SCHEMBL25204408 | 1.00 | TSHR (0.42) | TSHRHCAR2GAASMN1; SMN2PDCD1 | |
| SCHEMBL187423 | 1.00 | TSHR (0.42) | TSHRHCAR2GAASMN1; SMN2PDCD1 | |
| Hydrogen Peroxide SCHEMBL27935318 | 0.92 | TSHR (0.48) | TSHRHCAR2GAASMN1; SMN2PDCD1 | |
| SCHEMBL27539518 | 0.89 | TSHR (0.50) | TSHRHCAR2PDCD1CD274CA12 | |
| SCHEMBL19257 | 0.89 | TSHR (0.50) | TSHRHCAR2PDCD1CD274CA12 | |
| SCHEMBL444245 | 0.89 | TSHR (0.50) | TSHRHCAR2PDCD1CD274CA12 | |
| SCHEMBL19256 | 0.89 | TSHR (0.50) | TSHRHCAR2PDCD1CD274CA12 | |
| Bicarbonate SCHEMBL2348361 | 0.87 | TSHR (0.43) | TSHRHCAR2PDCD1CD274CA12 | |
| Benzene SCHEMBL27815751 | 0.87 | TSHR (0.43) | TSHRHCAR2GAASMN1; SMN2PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118317793-A | Methods for treating brain tumors and neuroblastomas | 阿斯利康(瑞典)有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2024141757-A1 | LSD1 MODULATORS | EXSCIENTIA AI LIMITED (GB) | 2024-07-04 | — | — | WO | disclosed |
| CN-111712492-B | Cyclotriazoles as LPA antagonists | 百时美施贵宝公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | disclosed |
| CN-117881402-A | Nucleotide and nucleoside therapeutic compositions, combinations, and uses related thereto | 埃默里大学 | 2024-04-12 | — | — | CN | disclosed |
| CN-117881661-A | Condensed heterocyclic derivative | 杨森科学爱尔兰无限公司 | 2024-04-12 | — | — | CN | disclosed |
| WO-2024031081-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-02-08 | — | — | WO | disclosed |
| CN-117295726-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-117279632-A | TAAR1 and serotonin modulators, pharmaceutical compositions thereof, and methods of use | 赛诺维信制药公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-110225904-B | Process for preparing cytotoxic benzodiazepine derivatives | 伊缪诺金公司 | 2023-10-27 | — | — | CN | disclosed |
| WO-2019195739-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | ABELA ALEXANDER RUSSELL (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019113476-A2 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019018395-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2018160824-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2018-09-07 | — | — | WO | disclosed |
| WO-2018107100-A1 | MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-14 | — | — | WO | disclosed |
| EP-2661436-A1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2013-11-13 | — | — | EP | disclosed |
| CN-102918027-A | Modulators of the gpr119 receptor and the treatment of disorders related thereto | ARENA PHARM INC | 2013-02-06 | — | — | CN | disclosed |
| WO-2012093169-A1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | WO | disclosed |
| EP-2231655-A2 | 4(-3-(-2-(PHENYL)MORPHOLINO)-2-OXOPYRROLIDIN-1-YL)-N-(THIAZOL-2-YL)BENZENESULFONAMIDE DERIVATI VES AND RELATED COMPOUNDS AS MODULATORS OF ION CHANNELS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009064747-A2 | 4(-3-(-2-(PHENYL)MORPHOLINO)-2-OXOPYRROLIDIN-1-YL)-N-(THIAZOL-2-YL)BENZENESULFONAMIDE DERIVATI VES AND RELATED COMPOUNDS AS MODULATORS OF ION CHANNELS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-22 | — | — | WO | disclosed |